Streptococcus salivarius capable of improving expression of secreted immune globulin of host and enhancing anti-infection ability of secreted immune globulin
By developing Streptococcus salivary CCFM1415, using its bacterial inactivated or lysate, it promotes the expression of PIGR and SIgA, and solves the problem of insufficient oral immunoglobulin levels in the prior art, significantly enhances the host's anti-infection ability, and provides New local immunomodulation methods have been developed.
Patent Information
- Application Number
- CN202411225198.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art has not yet found food-safe strains that can effectively improve the level of host oral secreted immunoglobulin A (sIgA), resulting in insufficient local immune capacity of the oral and related mucosa and lack of effective anti-infection methods.
A strain of Streptococcus salivary CCFM1415 was developed to prepare microbial preparations to promote the expression of the polymeric immunoglobulin receptor PIGR that transports IgA and Upregulate the expression of surface secreted immunoglobulin SIgA, reduce the load of pathogenic bacteria, and improve the pathological status of the infected site.
Streptococcus salivary CCFM1415 significantly increased the expression levels of PIGR and SIgA in mouse tongue tissue, reduced the load of Candida albicans, improved the invasion of oral pathogenic bacteria, enhanced the host's anti-infection ability, and provided new Local immune regulation means.
Smart Images

Figure CN118995515A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a strain of Streptococcus salivarius capable of improving the expression of host secretory immunoglobulin and enhancing the anti-infection ability thereof, belonging to the technical field of microorganisms. Background Art
[0002] In the field of modern biomedicine, the interaction between microorganisms and the host immune system has always been a hot topic of research. Streptococcus salivarius is a common oral microorganism belonging to Gram-positive bacteria and widely present in the human oral cavity. In recent years, studies have found that Streptococcus salivarius not only plays an important role in oral health, but also may enhance its resistance to pathogens by regulating the host's immune system. The regulation of the host immune system is of great significance for the prevention and treatment of infectious diseases, especially secretory immunoglobulin A (sIgA), which plays a key role as the first line of defense against bacterial and viral infections. sIgA is mainly secreted on mucosal surfaces, such as the oral cavity, gastrointestinal tract and respiratory tract, which are the first line of defense against pathogen invasion. Secretory immunoglobulin A (sIgA) plays a multifaceted protective role in the host's oral cavity. It effectively protects the oral mucosa from infection and damage by preventing pathogen adhesion, clearing foreign matter, regulating local immune responses, maintaining microecological balance and participating in immune surveillance.
[0003] At present, strategies to enhance host secretory immunoglobulins mainly focus on systemic immunoregulation and vaccination. Streptococcus salivarius is a common commensal bacterium naturally present in the oral cavity and pharynx. It not only plays an important role in maintaining the balance of oral microecology, but also has certain immunoregulatory functions. Recent studies have found that certain commensal bacteria in the intestine can stimulate the host's immune system and enhance the body's defense against infection. However, in the oral field, research on the immunoregulatory mechanism of oral commensal bacteria and their role in improving the expression of host secretory immunoglobulins is still relatively limited. At present, no food safety strains that can effectively enhance the host's sIgA level have been found. Compared with traditional vaccines and drugs, the use of Streptococcus salivarius strains that enhance the expression of host sIgA can effectively improve the local immune capacity of the oral cavity and related mucosa without causing systemic side effects. Therefore, it is necessary to develop a strain of Streptococcus salivarius that has the ability to significantly increase the expression of host secretory immunoglobulins and can safely and effectively enhance the host's anti-infection ability. The development of this strain will help fill the gap in existing immune enhancement technology and provide a new and effective means of local immunoregulation. Summary of the invention
[0004] In view of the shortcomings of the above-mentioned existing technologies, a strain of Streptococcus salivarius that can improve the expression of host secretory immunoglobulin and enhance its anti-infection ability is proposed. The goal is to provide a strain of Streptococcus salivarius that can improve the expression of host secretory immunoglobulin A (sIgA) and explore its application potential in improving the host's anti-infection ability. This strain of Streptococcus salivarius will help improve the local immune defense of the oral cavity and related mucosa, and provide a new solution for infection prevention and treatment.
[0005] The present invention provides a strain of Streptococcus salivarius CCFM1415, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on August 2, 2024, with a deposit number of GDMCC No: 64940.
[0006] In one embodiment of the present invention, the Streptococcus salivarius CCFM1415 is isolated from saliva samples of healthy people and has the following characteristics:
[0007] The colonies of the Streptococcus salivarius CCFM1415 after inoculation on the MRS solid medium for 48 hours are generally white, round, smooth and moist, and have neat edges. The Streptococcus salivarius CCFM1415 is a Gram-positive bacterium, facultative anaerobic, with an optimal growth temperature of 35-40°C and an optimal growth pH of 6.0-7.0.
[0008] The present invention also provides a postbiotic containing the inactivated bacteria of the Streptococcus salivarius CCFM1415 and / or its lysate.
[0009] The present invention also provides a microbial preparation containing the Streptococcus salivarius CCFM1415 or the postbiotic.
[0010] In one embodiment of the present invention, when the microbial preparation contains live cells, inactivated cells or fermentation broth of the Streptococcus salivarius CCFM1416, the content of the Streptococcus salivarius CCFM1415 in the microbial preparation is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.
[0011] The present invention also provides a product containing the Streptococcus salivarius CCFM1415 or the postbiotic, or the microbial preparation.
[0012] In one embodiment of the present invention, the product is a health product, a medicine or a daily chemical product.
[0013] In one embodiment of the present invention, the product comprises the Streptococcus salivarius CCFM1415 and conventional auxiliary materials.
[0014] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.
[0015] In one embodiment of the present invention, the medicine comprises the Streptococcus salivarius CCFM1415 and a pharmaceutically acceptable carrier.
[0016] In one embodiment of the present invention, the carrier includes one or more of fillers, binders, wetting agents, disintegrants, lubricants, and flavoring agents commonly used in medicine.
[0017] In one embodiment of the present invention, the daily chemical products include toothpaste, mouthwash and oral spray, and the daily chemical products do not contain living cells.
[0018] The present invention also provides the use of the Streptococcus salivarius CCFM1415 or the microbial preparation in preparing medicines for preventing and / or treating pathogenic bacteria infection.
[0019] In one embodiment of the present invention, the prevention and / or treatment of pathogenic bacterial infection includes at least one of the following aspects:
[0020] (1) Promote the expression of polymeric immunoglobulin receptor PIGR that transports IgA;
[0021] (2) Upregulate the expression of surface secretory immunoglobulin SIgA;
[0022] (3) reduce the load of pathogenic bacteria;
[0023] (4) Improve the pathological condition of the infected area.
[0024] In one embodiment of the present invention, the pathogenic bacteria include Candida albicans.
[0025] In one embodiment of the present invention, the infection site includes the oral cavity.
[0026] Beneficial Effects
[0027] The present invention provides a strain of Streptococcus salivarius CCFM1415, which is separated from the saliva of a healthy individual and has the effect of enhancing the host's oral immunity to resist infection by pathogenic bacteria, which is specifically embodied in:
[0028] (1) Promote the expression level of PIGR protein in oral epithelial cells;
[0029] (2) increase the gene and protein expression levels of polymeric immunoglobulin receptor PIGR in mouse tongue tissue;
[0030] (3) Increase the expression level of secretory immunoglobulin SIgA in mouse tongue tissue;
[0031] (4) reduce the load of Candida albicans in mouse tongue tissue;
[0032] (4) improving the pathological condition of individual tongue tissue;
[0033] (5) Improve the invasion of oral pathogen Candida albicans into mouse tongue tissue;
[0034] Therefore, Streptococcus salivarius CCFM1415 has great application prospects in products that regulate host oral immunity and resist oral pathogenic bacteria infections. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 :Effects of different bacterial lysates on PIGR expression in oral epithelial cells (HOK-16B);
[0036] Figure 2 :Flowchart of animal experiment design;
[0037] Figure 3 :Changes in the tongue mucosa of mice after intervention with Streptococcus salivarius;
[0038] Figure 4 :The effect of Streptococcus salivarius on the load of Candida albicans in the tongue tissue of mice;
[0039] Figure 5 :Effects of Streptococcus salivarius on the expression of PIGR and SIgA in mouse tongue tissue;
[0040] Figure 6 :Histopathological evaluation of mouse tongue;
[0041] Figure 7 : Pathological evaluation of PAS staining of mouse tongue tissue.
[0042] Biomaterial Deposit
[0043] A strain of Streptococcus salivarius CCFM1415, taxonomically named Streptococcus salivarius, was deposited in the Guangdong Provincial Microbiological Culture Collection on August 2, 2024, with the deposit number GDMCC No: 64940. The deposit address is the 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences. DETAILED DESCRIPTION
[0044] To make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings. The strains, cells and animals involved in the following embodiments are as follows: SPF-grade BALB / c mice, female, 6 weeks old, weighing 15-18g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Production License No. SCXK (Beijing) 2012-0001). Salivarius Streptococcus OJSWX12B1 comes from the strain bank of the Biotechnology Center of Jiangnan University. Candida albicans SC5314 was purchased from Ningbo Mingzhou Technology Co., Ltd. Human oral keratinocytes HOK-16B were purchased from Qingqi (Shanghai) Biotechnology Development Co., Ltd.
[0045] The culture medium involved in the following examples is as follows:
[0046] BHI liquid medium: peptone 10.0 g / L, dehydrated calf brain extract powder 12.5 g / L, dehydrated bull heart extract powder 5.0 g / L, sodium chloride 5.0 g / L, glucose 2.0 g / L, disodium hydrogen phosphate 2.5 g / L, pH 7.2-7.4;
[0047] BHI solid medium: peptone 10.0 g / L, dehydrated calf brain extract powder 12.5 g / L, dehydrated ox heart extract powder 5.0 g / L, sodium chloride 5.0 g / L, glucose 2.0 g / L, disodium hydrogen phosphate 2.5 g / L, agar 20.0 g / L, pH 7.2-7.4;
[0048] Complete cell culture medium: 89% (v / v) DMEM medium + 10% (v / v) fetal bovine serum + 1% (v / v) 100× penicillin and streptomycin mixed solution (penicillin content in the mixed solution is 10000U / mL, streptomycin concentration is 10mg / mL), which is the cell culture medium for human oral keratinocytes HOK-16B.
[0049] The bacterial liquid involved in the following examples is as follows:
[0050] Preparation of Streptococcus bacterial solution:
[0051] (1) Preparation of seed solution:
[0052] A small amount of Streptococcus salivarius CCFM1415 and OJSWX12B1 bacterial liquid was dipped into a sterile inoculation loop and activated in BHI solid medium, and cultured at 37°C for 48 hours. Subsequently, a single colony was picked and inoculated into BHI liquid medium, and cultured in a 37°C incubator for 18 hours to prepare the seed liquid.
[0053] (2) The prepared seed solution was inoculated in BHI liquid medium at a 2% (v / v) inoculation rate, cultured in a 37°C incubator for 18 h, centrifuged and concentrated to collect the bacteria and count the colonies, and stored in a -80°C refrigerator with 30% glycerol for later use. Before intervention, the glycerol was removed by centrifugation and the concentration of the bacterial suspension was adjusted to 1×10 10 CFU / mL.
[0054] Bacterial lysis buffer:
[0055] (1) According to the preparation method of Streptococcus salivarius bacterial liquid, the bacterial liquid was centrifuged to obtain bacterial slurry, and the suspension concentration was adjusted to 5×10 9 CFU / mL, and after homogenization in a high-pressure homogenizer (800-1200 MPa) for 10 times, the cells were filtered through a 0.22 μm filter membrane to obtain the bacterial lysate prepared from the bacterial suspension of the corresponding concentration.
[0056] (2) Preparation of cell culture medium containing 5% (v / v) Streptococcus salivarius cell lysate:
[0057] The bacterial lysate obtained above was added to a complete cell culture medium at a ratio of 5% (v / v) to obtain a cell culture medium containing the bacterial lysate, which included 84% (v / v) DMEM culture medium + 10% (v / v) fetal bovine serum + 1% (v / v) 100× penicillin and streptomycin mixed solution (the penicillin content in the mixed solution was 10000 U / mL, and the streptomycin concentration was 10 mg / mL) + 5% (v / v) Streptococcus salivarius bacterial lysate.
[0058] Candida albicans suspension:
[0059] (1) Preparation of seed solution:
[0060] Candida albicans SC5314 was inoculated into YPD medium and cultured in a shaking incubator at 28°C for 18 h to prepare a seed solution.
[0061] (2) The Candida albicans seed solution was inoculated into YPD medium at a 2% inoculum volume, and after incubation at 28°C for 18 h, the cells were collected by centrifugation and resuspended in sterile saline to a concentration of 1×10 7 CFU / mL.
[0062] Embodiment 1: separation and identification of Streptococcus salivarius CCFM1415
[0063] The specific steps are as follows:
[0064] Collect non-irritated saliva from healthy people and store it in 30% glycerol in a -80℃ refrigerator or place the sample in dry ice and transfer it to the laboratory for immediate bacterial isolation and culture. After the sample is thawed, pipette 0.2mL into 1.8mL sterile saline to obtain 10 -1 Dilution, then draw 0.5mL 10 -1 Dilute in 4.5 mL of saline to obtain 10 -2 Dilution, follow this procedure to obtain 10 -3 , 10 -4 , 10 -5 , 10 -6 Gradient dilution. Take 10 -4 , 10 -5 , 10 -6 Place 1 mL of each dilution in a plate, pour into BHI solid culture medium, mix gently, and after the culture medium solidifies, invert and culture at 37°C for 48 h.
[0065] Select colonies of different morphologies and streak them on BHI plates for purification. Pick the purified single colony and inoculate it into 10mL liquid culture medium and culture it at 37℃ for 18h. Take 1.0mL of cultured bacterial solution, centrifuge it at 5000r / min for 3min, discard the supernatant, add 1.0mL of sterile saline to wash 3 times, resuspend it in 1.0mL of sterile water, and use it as a template for bacterial identification. Set up a PCR system with a volume of 20μL, add 0.5μL of forward primer (10μM), 0.5μL of reverse primer (10μM), 10μL of 2×TaqMixture, 0.5μL of bacterial suspension, and 8.5μL of double distilled water. Primer information is shown in Table 1, and the 16S rDNA sequence is shown in SEQ ID NO.1.
[0066] Table 1: Primer information
[0067]
[0068] For the correctly identified bacterial species, take 1.0 mL of bacterial solution into a 2 mL bacterial preservation tube, centrifuge at 6000 r / min for 3 min, remove the supernatant in a clean bench, add 1 mL of 30% sterile glycerol, mix thoroughly with a vortex oscillator, and store in a -80°C refrigerator.
[0069] The obtained 16S sequence was confirmed by NCBI BLAST (http: / / www.ncbi.nlm.nih.gov / BLAST). The closer the Query Cover and Identification are to 100%, the more feasible it is. If there are multiple species in the comparison results, the Complete genome species will be prioritized while taking the numerical values into consideration. The results showed that the strain was Streptococcus salivarius, named Streptococcus salivarius CCFM1415.
[0070] Example 2: Ability of Streptococcus salivarius bacterial lysate to promote the expression of polymeric immunoglobulin receptor PIGR in oral epithelial cells
[0071] The specific steps are as follows:
[0072] Oral epithelial HOK-16B cells were revived and passaged three times, and the cell concentration was adjusted to 5×10 5 / mL, inoculate 2mL of the cell suspension at this concentration in a 6-well cell culture plate, incubate for 24h under 5% CO2, 37℃, and then add sample intervention. Set up a control group and a strain sample treatment group. The control group was added with a cell culture solution containing 5% PBS; the strain sample treatment group was added with a cell culture solution containing 5% bacterial lysis solution, and 3 replicates were set in each group. After 24h of intervention in the 6-well plate, the cell supernatant was collected and the content of secretory component SC in the supernatant was detected according to the instructions of the ELISA kit to characterize the content of polymeric immunoglobulin receptor PIGR.
[0073] Table 2: Group information table
[0074]
[0075] The results are as follows Figure 1 As shown in the figure, after 24 hours of intervention, the PIGR content in the blank group supernatant was 353.72pg / mg, and the PIGR content in the CCFM1415 bacterial lysate group (CCFM1415-P) was 479.15pg / mg compared with the blank control group, which could significantly upregulate the expression of PIGR in oral epithelial cells (p < 0.05); while there was no significant difference between the OJSWX12B1 bacterial lysate group (OJSWX12B1-P) and the blank control group. Therefore, at the cellular level, CCFM1415-P can promote the expression of PIGR in oral epithelial cells, regulate the host's innate immunity, and enhance the host's ability to resist infection by pathogenic bacteria in the oral cavity.
[0076] Example 3: Application of Streptococcus salivarius CCFM 1415 in regulating host immunity
[0077] 1. Preparation of Streptococcus salivarius suspension
[0078] Preparation of Streptococcus salivarius CCFM1415 bacterial suspension: Use a sterile inoculation loop to dip a small amount of Streptococcus salivarius CCFM1415 bacterial suspension into BHI solid medium for activation, and culture at 37°C for 48 hours. Then pick a single colony and inoculate it into BHI liquid medium, and culture it in a 37°C incubator for 18 hours to prepare the seed solution.
[0079] The prepared seed solution was inoculated in BHI liquid medium at 2% (v / v) inoculation volume, cultured in a 37°C incubator for 18 h, centrifuged and concentrated to collect the bacteria and count the colonies, and stored in a -80°C refrigerator with 30% glycerol for later use. Before intervention, the glycerol was removed by centrifugation and the concentration of the bacterial suspension was adjusted to 1×10 10 CFU / mL.
[0080] 2. Experimental animals and strains:
[0081] SPF BALB / c mice, female, 6 weeks old, weighing 15-18 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Production License No. SCXK (Beijing) 2012-0001). Salivarius CCFM1415 was from the strain bank of the Biotechnology Center of Jiangnan University. Candida albicans SC5314 was purchased from Ningbo Mingzhou Technology Co., Ltd. Figure 2 Table 3 shows the animal experiment process.
[0082] Table 3: Animal experimental plan and grouping
[0083]
[0084]
[0085] Before the experiment, all mice were randomly divided into 3 groups according to their body weight, and the mice were placed in an environment with a 22℃-24℃ and 12-hour light-dark cycle to adapt for one week. Referring to Table 2, all groups of mice were fed normally throughout the experiment. The blank group mice were treated with normal saline instead of probiotics throughout the experiment, and immunosuppressants were injected on the 14th and 16th days. The Candida albicans model group was treated with normal saline instead of probiotics on days 0-17, and immunosuppressants were injected on the day before and after Candida albicans infection (the infection method of Candida albicans was: anesthetizing mice, soaking cotton balls of the same size in a concentration of 1×10 7 CFU / ml of Candida albicans suspension, and then inoculated under the tongue of mice, the action time is about 60min). The intervention group was continuously intervened with Streptococcus salivarius CCFM1415 for 17 days (0-17 days), immunosuppressants were injected on the 14th and 16th days, and Candida albicans infection was performed on the 15th day. The specific operation method of all interventions was oral irrigation with a No. 8 gavage needle.
[0086] The specific steps are as follows:
[0087] (1) Intervention experiment: Starting from day 0, the details are as follows:
[0088] Blank control group: Use No. 8 elbow gavage needle to draw 30ul of sterile saline for oral irrigation once a day.
[0089] Model group mice: Use a No. 8 elbow gavage needle to draw 30ul of sterile saline for oral irrigation once a day.
[0090] S. salivarius CCFM1415 group: 30ul of S. salivarius CCFM1415 suspension (1×10 10 CFU / mL) for oral rinse once a day.
[0091] (2) Immunosuppression: All groups of mice were immunosuppressed on days 14 and 16 by subcutaneous injection of 0.2 ml of 225 mg / kg cortisone acetate.
[0092] (3) Infection experiment (modeling period): All groups except the blank group were anesthetized on the 15th day and soaked in 1×10 7 CFU / mL of Candida albicans suspension was then inoculated sublingually in mice for about 60 minutes, and then the cotton ball was removed.
[0093] After the intervention, the tongue tissue of mice was sampled for subsequent tissue pathogen load, HE tissue pathology analysis, PAS pathogen hyphae invasion analysis, and detection of the expression levels of related antibacterial indicators in the tongue tissue.
[0094] 3. Experimental results:
[0095] (1) Changes in the mucosal surface of mouse tongue
[0096] After the intervention, the surface of the tongue mucosal tissue of mice in each group was observed to evaluate the infection degree of Candida albicans in the oral cavity. Figure 3As shown in the figure, the tongue dorsum of the mice in the control group was light red, the tongue was smooth and moist, and there was no colonization of pathogenic bacteria Candida albicans; the tongue of the mice in the model group was covered with a thick pseudomembrane formed by Candida albicans, which adhered to the surface of the mouse tongue in pieces, and the mouse tongue showed symptoms of atrophy. After the intervention of Streptococcus salivarius CCFM1415, the colonization of Candida albicans on the mucosal surface of the mouse tongue was greatly reduced compared with the model group, and only a few points had pseudomembranes of Candida albicans. The appearance of the mouse tongue tissue was comparable to that of the blank group mice, indicating that Streptococcus salivarius CCFM1415 can resist the colonization of Candida albicans in the oral cavity to a large extent and play a role in resisting pathogenic bacteria infection in the host's oral cavity.
[0097] (2) Candida albicans load in mouse tongue tissue
[0098] After the intervention, the tongue tissues of mice were homogenized and counted to assess the colonization of Candida albicans in the tongue tissues. Figure 4 As shown in Figure 2, the average colonization of Candida albicans in the tongue tissue of mice in the model group was about 7.52×10 5 CFU / g; the load of pathogenic bacteria Candida albicans in tongue tissue of the S. salivarius CCFM1415 group after intervention was about 3.17×10 4 CFU / g showed a significant downward trend compared with the model group (P < 0.01). Therefore, S. salivarius CCFM1415 can reduce the colonization of pathogenic bacteria Candida albicans in the oral cavity of mice and play an anti-pathogenic bacterial infection role.
[0099] (3) Expression of PIGR and SIgA in mouse tongue tissue
[0100] After the intervention, the expression of PIGR and SIgA in the tongue tissue of mice was evaluated. Figure 5 As shown in Figure A, the average expression of PIGR between the blank group and the model group was 47.11pg / mg and 40.40pg / mg, respectively, and there was no significant difference between the two groups, because all groups were injected with immunosuppressants, and the blank group and the model group did not undergo probiotic intervention, so there was no significant difference between the indicators. The expression of PIGR in the tongue tissue of mice in the S. salivarius CCFM1415 group after intervention was 51.37pg / mg, which was significantly higher than that in the model group (P < 0.05). Therefore, it is speculated that S. salivarius CCFM1415 can upregulate the expression of PIGR, a polymeric immunoglobulin receptor that transports IgA, in the tongue tissue, thereby further increasing the expression of mucosal SIgA in vivo and enhancing the anti-pathogenic bacteria infection effect in the mouse oral cavity.
[0101] The upregulation of PIGR increases the binding of IgA in tissues, thereby increasing the production of SIgA on mucosal surfaces. Therefore, the expression level of SIgA in mouse tongue tissue was further evaluated in vivo. Figure 5 As shown in Figure B, the average expression of SIgA between the blank group and the model group was 180.95 ng / mg and 125.56 ng / mg, respectively, and there was no significant difference in the expression between the two groups. The expression of SIgA in the tongue tissue of mice in the S. salivarius CCFM1415 group after intervention was 175.55 ng / mg, which was significantly higher than that in the model group (P < 0.05). In summary, S. salivarius CCFM1415 can upregulate the expression of secretory immunoglobulin SIgA on the surface of the tongue mucosa, thereby preventing the invasion of pathogens on the mucosal surface and enhancing the host's oral anti-infection ability.
[0102] (4) Histopathological analysis of mouse tongue
[0103] After the intervention, longitudinal sections of the mouse tongue tissue were observed. Figure 6 As shown in the figure, the filiform papillae on the dorsum of the tongue tissue of the blank group mice were neatly arranged, the epithelial stratum corneum was intact and smooth, the boundaries between the epithelial layers were clear, and there was no recruitment of inflammatory cells. In the model group, the epithelial stratum corneum was severely damaged, the filiform papillae on the dorsum of the tongue were basically non-existent, and there was a large number of inflammatory cells recruited and small abscesses formed in some locations. After the intervention of S. salivarius CCFM1415, the pathological sections of the mouse tongue tissue were similar to those of the blank group, indicating that S. salivarius CCFM1415 can resist the invasion of oral pathogens and protect the oral mucosal tissue from damage to a certain extent.
[0104] (6) PAS staining analysis of mouse tongue tissue
[0105] After the intervention, PAS staining was performed on the tongue tissue of mice to observe the invasion of Candida albicans hyphae into the tongue tissue. Figure 7 As shown in the figure, no hyphae were observed to invade the tongue tissue by PAS staining in the blank group; PAS staining in the model group showed that a large number of hyphae invaded the epithelial layer of the tongue tissue, and a large number of inflammatory cells were recruited around these hyphae. Most of these hyphae invaded the deep layer of the epithelial tissue at a vertical or inclined angle to damage the tissue. After intervention with S. salivarius CCFM1415, the PAS staining of the mouse tongue tissue was similar to that of the blank group, indicating that S. salivarius CCFM1415 can resist the invasion of oral pathogens Candida albicans into oral mucosal tissues to a certain extent, thereby playing a role in resisting oral pathogen infection.
[0106] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A strain of Streptococcus salivarius CCFM1415, characterized in that: The Streptococcus salivarius CCFM1415 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on August 2, 2024, with the collection number GDMCCNo:64940.
2. A postbiotic, characterized in that: The postbiotics include the inactivated bacteria of Streptococcus salivarius CCFM1415 and / or its lysate according to claim 1.
3. A microbial preparation, characterized in that: The microbial preparation comprises the Streptococcus salivarius CCFM1415 according to claim 1 or the postbiotic according to claim 2.
4. A product, characterized in that The product contains the Streptococcus salivarius CCFM1415 described in claim 1, or the postbiotics described in claim 2, or the microbial preparation described in claim 3.
5. The product according to claim 4, characterized in that The product includes health products, medicines or daily chemical products; the product includes the Streptococcus salivarius CCFM1415 and conventional auxiliary materials.
6. The product according to claim 5, characterized in that The dosage form of the medicine includes powder, granule, capsule, tablet, pill or oral solution.
7. The product according to claim 6, characterized in that The daily chemical products include toothpaste, mouthwash and oral spray.
8. Use of the Streptococcus salivarius CCFM1415 according to claim 1, or the postbiotic according to claim 2, or the microbial preparation according to claim 3 in the preparation of medicines for preventing and / or treating pathogenic bacteria infections.
9. The use according to claim 8, characterized in that: The prevention and / or treatment of pathogenic bacteria infection includes at least one of the following aspects: (1) Promote the expression of polymeric immunoglobulin receptor PIGR that transports IgA; (2) Upregulate the expression of surface secretory immunoglobulin SIgA; (3) reduce the load of pathogenic bacteria; (4) Improve the pathological condition of the infected area.
10. The use according to claim 9, characterized in that: The pathogenic bacteria include Candida albicans; optionally, the infection site includes the oral cavity.
Citation Information
Cited By
Streptococcus salivarius CCFM1399 for relieving bone resorption and periodontal tissue injury and metaplasm of streptococcus salivarius CCFM1399
CN119842518A
